Studies in older AML adults using CGA
| Reference . | Disease and no. of patients . | Therapy . | Variables . | CGA variables . | Outcomes: impact on OS . | ||||
|---|---|---|---|---|---|---|---|---|---|
| Clinical . | Disease . | Treatment . | Risk groups . | OS . | P . | ||||
| 25 | MDS (n = 63) AML (n = 132) | Non-IC* (n = 120); IC (n = 65) | BM blast >20%, cytogenetics, HCT-CI ≥3 | KPS <80, impaired ADLs (Barthel index >100), high fatigue score (EORTC QLQ-C30 ≥50) | Low risk (0 risk features) | 744 d | |||
| Intermediate risk (1 to 2 risk features) | 231 d | ||||||||
| High risk (3 risk features) | 51 d | <.001 | |||||||
| 28 | AML (n = 74) | IC | Hemoglobin, age, sex, ECOG PS, cytogenetics | Prior MDS | Cognitive impairment (CI) (Modified MMSE < 77), impaired PF (SPPB <9) | CI vs no CI | 5.2 vs 15.6 mo | .002 | |
| Impaired PF vs not impaired PF | 6 vs 16.8 mo | .018 | |||||||
| 26 | AML (n = 101) | Non-IC* (n= 65); IC (n = 35) | Age >72 y, ECOG PS >1, cytogenetics, HCT-CI >1 | Secondary AML | CR; allogeneic HSCT | Strenuous activity difficulty, pain (more often vs less often) | Less vs more difficulty with strenuous activity | 11.8 vs 4.4 mo | <.001 |
| Less vs more pain | 1.3 vs 4.1 mo | <.002 | |||||||
| HCT-CI score ≤1 vs >1 | 11.8 vs 4.4 mo | <.001 | |||||||
| Reference . | Disease and no. of patients . | Therapy . | Variables . | CGA variables . | Outcomes: impact on OS . | ||||
|---|---|---|---|---|---|---|---|---|---|
| Clinical . | Disease . | Treatment . | Risk groups . | OS . | P . | ||||
| 25 | MDS (n = 63) AML (n = 132) | Non-IC* (n = 120); IC (n = 65) | BM blast >20%, cytogenetics, HCT-CI ≥3 | KPS <80, impaired ADLs (Barthel index >100), high fatigue score (EORTC QLQ-C30 ≥50) | Low risk (0 risk features) | 744 d | |||
| Intermediate risk (1 to 2 risk features) | 231 d | ||||||||
| High risk (3 risk features) | 51 d | <.001 | |||||||
| 28 | AML (n = 74) | IC | Hemoglobin, age, sex, ECOG PS, cytogenetics | Prior MDS | Cognitive impairment (CI) (Modified MMSE < 77), impaired PF (SPPB <9) | CI vs no CI | 5.2 vs 15.6 mo | .002 | |
| Impaired PF vs not impaired PF | 6 vs 16.8 mo | .018 | |||||||
| 26 | AML (n = 101) | Non-IC* (n= 65); IC (n = 35) | Age >72 y, ECOG PS >1, cytogenetics, HCT-CI >1 | Secondary AML | CR; allogeneic HSCT | Strenuous activity difficulty, pain (more often vs less often) | Less vs more difficulty with strenuous activity | 11.8 vs 4.4 mo | <.001 |
| Less vs more pain | 1.3 vs 4.1 mo | <.002 | |||||||
| HCT-CI score ≤1 vs >1 | 11.8 vs 4.4 mo | <.001 | |||||||
BM, bone marrow; EORTC QLQ-C30, European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire-C30; MDS, myelodysplastic syndrome; MMSE, Mini-Mental State Examination.
Non-IC includes best supportive care, HMAs such as decitabine and azacitidine, and other agents such as single-agent 6-mercaptopurine.